Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study
Journal of Gastroenterology · 2026-08 · 61 (8) · 1170-1180
DOI: 10.1007/s00535-026-02412-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 12.04.2026. Verfasst von Hisashi Kosaka und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, 573-1010, Japan. kosaka.his@kmu.ac.jp. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Durvalumab plus gemcitabine–cisplatin (GCD) has become a standard first-line therapy for advanced biliary tract cancer (BTC) following the TOPAZ-1 trial. However, whether the survival benefit observed in trial-eligible patients can be generalized to broader real-world populations remains uncertain. We evaluated the impact of TOPAZ-1 eligibility on the effectiveness of GCD in routine clinical practice.
Methods
In this multicenter retrospective cohort study, 610 patients with unresectable or recurrent BTC treated with first-line GCD ( n = 268) or gemcitabine–cisplatin (GC) ( n = 342) at 19 Japanese institutions were analyzed. Patients were classified according to TOPAZ-1 eligibility criteria. Overall survival (OS) was compared between treatment groups in the entire cohort and stratified by eligibility status. Multivariable Cox models were constructed separately for eligible and ineligible patients.
Results
Among 610 patients, 324 (53.1%) met TOPAZ-1 eligibility criteria. In the overall cohort, GCD was associated with longer OS than GC (median, 13.7 vs 11.3 months; p = 0.009). Among eligible patients, GCD significantly improved OS compared with GC (18.0 vs 13.1 months; p = 0.004), whereas no significant difference was observed among ineligible patients (10.8 vs 10.0 months; p = 0.675). However, the interaction between treatment and TOPAZ-1 eligibility was not statistically significant ( p for interaction = 0.162).
Conclusions
In this real-world cohort, the survival benefit of GCD appeared to be primarily observed in patients meeting TOPAZ-1 eligibility criteria. Trial-based eligibility may influence the magnitude of benefit from immunochemotherapy in advanced BTC, underscoring the importance of patient selection in routine practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, 573-1010, Japan. kosaka.his@kmu.ac.jp.
- Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka, Japan.
- Department of Hepatobiliary-Pancreatic Surgery, Osaka Metropolitan University, Osaka, Japan.
- Department of Surgery, Nara Medical University, Kashihara, Japan.
- Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
- Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
ORCID-Profile: Hisashi Kosaka
Zitieren
APA
Kosaka, H., Sugimoto, R., Kinoshita, M., Yasuda, S., Kakizaki, S., Sakata, J., Yamai, K., Hatanaka, T., Yamamoto, Y., Sato, T., Ishikawa, T., Morikawa, T., Hanaoka, J., Mori, H., Toyoda, H., Sanuki, T., Yokoi, M., Shibata, H., Fukuda, K., …, & Kaibori, M. (2026). Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study. Journal of Gastroenterology, 61(8), 1170-1180. https://doi.org/10.1007/s00535-026-02412-6
Vancouver
Kosaka H, Sugimoto R, Kinoshita M, Yasuda S, Kakizaki S, Sakata J, et al. Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study. Journal of Gastroenterology. 2026;61(8):1170-1180. doi:10.1007/s00535-026-02412-6
BibTeX
@article{Kosaka2026,
author = {Kosaka, Hisashi and Sugimoto, Rie and Kinoshita, Masahiko and Yasuda, Satoshi and Kakizaki, Satoru and Sakata, Jun and Yamai, Kiyonori and Hatanaka, Takeshi and Yamamoto, Yusuke and Sato, Toshifumi and Ishikawa, Toru and Morikawa, Takanori and Hanaoka, Jun and Mori, Haruki and Toyoda, Hidenori and Sanuki, Tsuyoshi and Yokoi, Misaki and Shibata, Hiroyuki and Fukuda, Koji and Kawata, Kazuhito and Amaya, Koji and Ito, Takashi and Hidaka, Masaaki and Naganuma, Atsushi and Sugimachi, Keishi and Kaibori, Masaki},
title = {Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine–cisplatin in advanced biliary tract cancer: a multicenter real-world study},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {8},
pages = {1170--1180},
doi = {10.1007/s00535-026-02412-6}
}
EUVIMED